Hepatitis C: Pan-Genotypic DAA Regimens, Treatment Simplification, and Cure Rates

Pan-Genotypic Regimens: Sofosbuvir/Velpatasvir and Glecaprevir/Pibrentasvir

Hepatitis C treatment has undergone the most dramatic transformation of any chronic infectious disease in the past two decades. What was once an interferon-based regimen requiring 24-48 weeks of injections with significant side effects and cure rates below 50% is now an 8-12 week oral course with SVR rates consistently above 95% — approaching a functional cure. For the gastroenterologist, hepatologist, infectious disease specialist, or primary care physician, the clinical challenge has shifted from "can we cure this patient?" to "how do we reach the millions who remain undiagnosed or untreated?" The simplified treatment algorithms now support primary care-initiated HCV treatment without specialist referral for most patients, making this a condition that every clinician who orders routine blood work should be prepared to manage.

Two pan-genotypic regimens dominate HCV treatment. Sofosbuvir/velpatasvir (Epclusa, 400/100 mg daily for 12 weeks) achieved SVR12 rates of 99% in genotype 1, 100% in genotype 2, 95% in genotype 3, and 99-100% in genotypes 4-6 in the ASTRAL trials[1]. Glecaprevir/pibrentasvir (Mavyret, 300/120 mg daily for 8 weeks in non-cirrhotic treatment-naive patients) demonstrated SVR12 of 97-100% across all genotypes in the ENDURANCE and EXPEDITION trials[2]. The shorter 8-week course of glecaprevir/pibrentasvir offers practical advantages for treatment-naive non-cirrhotic patients.

Simplified Treatment Algorithm

The AASLD-IDSA simplified treatment algorithm allows initiation without genotype testing, liver biopsy, or specialist consultation for treatment-naive adults without known cirrhosis, hepatitis B coinfection, prior HCV treatment, or current pregnancy. Under the simplified approach, either pan-genotypic regimen can be prescribed by primary care providers after confirming HCV RNA positivity, checking baseline renal function, and reviewing drug-drug interactions. This approach supports HCV elimination goals by reducing barriers to treatment in primary care and community health settings.

Special Populations: Cirrhosis and Renal Impairment

For compensated cirrhosis (Child-Pugh A), sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 12 weeks (extended from 8) are recommended. Decompensated cirrhosis (Child-Pugh B/C) requires a protease inhibitor-free regimen: sofosbuvir/velpatasvir for 12 weeks, often with ribavirin weight-based dosing (1000-1200 mg daily)[6] to optimize SVR. Glecaprevir/pibrentasvir is contraindicated in decompensated cirrhosis due to hepatic clearance of protease inhibitors. For patients with eGFR <30 mL/min, glecaprevir/pibrentasvir is preferred as it is renally safe, while sofosbuvir-based regimens carry theoretical nephrotoxicity concerns (though real-world data show acceptable safety at reduced eGFR).